Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results
Incyte Corp. (NASDAQ: INCY ) on Tuesday reported better-than-expected second-quarter results and raised its full-year sales guidance. The biopharmaceutical company reported adjusted earnings of $3.09 per share, beating the analyst consensus estimate of $2.12. Revenue rose 38% year over year to $1.67 billion, topping th